🇺🇸 Mycophenylate mofetil in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Acute Respiratory Failure — 1 report (10%)
- Candidiasis — 1 report (10%)
- Cushing^S Syndrome — 1 report (10%)
- Dermatitis Exfoliative — 1 report (10%)
- Dry Throat — 1 report (10%)
- Dysphonia — 1 report (10%)
- Hypotension — 1 report (10%)
- Medication Error — 1 report (10%)
- Myositis — 1 report (10%)
- Off Label Use — 1 report (10%)
Other Immunology approved in United States
Frequently asked questions
Is Mycophenylate mofetil approved in United States?
Mycophenylate mofetil does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Mycophenylate mofetil in United States?
Masonic Cancer Center, University of Minnesota is the originator. The local marketing authorisation holder may differ — check the official source linked above.